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Abstract
Aims: Our aim was to compare the safety and efficacy of a novel, ultrathin strut, biodegradable poly-
mer sirolimus-eluting stent (BP-SES) with a thin strut, durable polymer everolimus-eluting stent (DP-EES) 
in a pre-specified subgroup of patients with acute ST-segment elevation myocardial infarction (STEMI) 
enrolled in the BIOSCIENCE trial.
Methods and results: The BIOSCIENCE trial is an investigator-initiated, single-blind, multicentre, ran-
domised non-inferiority trial (NCT01443104). Randomisation was stratified according to the presence or 
absence of STEMI. The primary endpoint, target lesion failure (TLF), is a composite of cardiac death, tar-
get vessel myocardial infarction, and clinically indicated target lesion revascularisation within 12 months. 
Between February 2012 and May 2013, 407 STEMI patients were randomly assigned to treatment with 
BP-SES or DP-EES. At one year, TLF occurred in seven (3.4%) patients treated with BP-SES and 17 
(8.8%) patients treated with DP-EES (RR 0.38, 95% CI: 0.16-0.91, p=0.024). Rates of cardiac death were 
1.5% in the BP-SES group and 4.7% in the DP-EES group (RR 0.31, 95% CI: 0.08-1.14, p=0.062); rates 
of target vessel myocardial infarction were 0.5% and 2.6% (RR 0.18, 95% CI: 0.02-1.57, p=0.082), respec-
tively, and rates of clinically indicated target lesion revascularisation were 1.5% in the BP-SES group ver-
sus 2.1% in the DP-EES group (RR 0.69, 95% CI: 0.16-3.10, p=0.631). There was no difference in the risk 
of definite stent thrombosis.
Conclusions: In this pre-specified subgroup analysis, BP-SES was associated with a lower rate of target 
lesion failure at one year compared to DP-EES in STEMI patients. These findings require confirmation in 
a dedicated STEMI trial.
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Introduction
Acute ST-segment elevation myocardial infarction (STEMI) con-
fers an increased risk of adverse outcome compared to stable coro-
nary artery disease which extends beyond the periprocedural phase 
of primary percutaneous coronary intervention (PCI). Plaque 
characteristics of culprit lesions, thrombus burden and persistent 
inflammation are hallmarks of STEMI patients which increase 
the risk of delayed arterial healing and vessel remodelling, as 
reflected by higher rates of incomplete stent strut coverage1,2 and 
malapposition3.
Biodegradable polymer-based metallic drug-eluting stents 
(BP-DES) have been observed to reduce the rate of major adverse 
cardiac events (MACE) compared to bare metal stents (BMS) 
among patients with STEMI undergoing primary PCI at one 
year4. BP-DES have also been associated with a favourable heal-
ing response in intravascular imaging studies5, and demonstrated 
a lower incidence of MACE throughout long-term follow-up com-
pared to early-generation durable polymer drug-eluting stents 
among patients with STEMI6,7. A randomised comparison of dur-
able polymer everolimus-eluting stents (DP-EES) versus BMS 
failed to show superiority of DP-EES with regard to the patient-
oriented primary composite endpoint of all-cause death, recurrent 
myocardial infarction, and repeat revascularisation at one year. 
However, rates of target lesion revascularisation and definite and 
probable stent thrombosis were significantly lower in patients 
treated with DP-EES compared with BMS8.
New-generation DES with cobalt-chromium platforms, reduced 
stent strut thickness and biocompatible polymers have been shown 
to be safe and effective in unselected patient populations and rep-
resent the current standard of care in patients undergoing PCI9. 
The combination of biodegradable polymers with thin strut cobalt-
chromium platforms represents the next iteration of technological 
progress. In the randomised controlled BIOSCIENCE (biode-
gradable polymer sirolimus-eluting stent versus durable polymer 
everolimus-eluting stent for percutaneous coronary revascularisa-
tion) trial, an ultrathin strut cobalt-chromium stent releasing siroli-
mus from a biodegradable poly-L-lactic acid (PLLA) polymer 
(BP-SES) was non-inferior compared to a thin strut DP-EES in 
a patient population reflecting routine clinical practice10. We pre-
sent the results of a pre-specified subgroup analysis of patients 
with STEMI enrolled into the BIOSCIENCE trial.
Methods
STUDY DESIGN AND PATIENTS
The BIOSCIENCE trial is an investigator-initiated, single-
blind, multicentre, randomised non-inferiority trial comparing an 
ultrathin strut (60 μm for stent diameters up to 3.0 mm, 80 μm for 
stent diameters >3.0 mm) cobalt-chromium L605 stent platform 
covered with an amorphous silicon-carbide layer and a biodegrad-
able PLLA polymer releasing sirolimus (Orsiro; Biotronik AG, 
Bülach, Switzerland) with a thin strut cobalt-chromium, durable 
polymer everolimus-eluting stent (XIENCE PRIME/Xpedition®; 
Abbott Vascular, Santa Clara, CA, USA) in a patient population 
with minimal exclusion criteria in nine centres in Switzerland. 
In summary, all patients aged 18 years or older with at least one 
coronary lesion with >50% diameter de novo stenosis or resteno-
sis in a native coronary artery or a bypass graft suitable for stent 
implantation were eligible for inclusion. There were no restric-
tions in terms of number of vessels or lesions treated. Inclusion 
and exclusion criteria as well as detailed characteristics of the 
study devices have been reported previously11. The study was 
approved by the institutional ethics committees of all participating 
sites and complied with the Declaration of Helsinki. All study par-
ticipants provided written informed consent. The trial is registered 
with ClinicalTrials.gov (NCT01443104). The trial was supported 
by an unrestricted grant from Biotronik, Bülach, Switzerland. The 
funding source had no role in the study design, data collection, 
data monitoring, data analysis, or data interpretation.
RANDOMISATION
Patients were randomly allocated in a 1:1 ratio to BP-SES or 
DP-EES immediately after diagnostic angiography and prior to 
PCI. Randomisation was computer generated and stratified accord-
ing to the presence or absence of STEMI, per site. Sequentially 
numbered, opaque, sealed envelopes were used as a back-up in 
case of malfunction of the web-based randomisation system.
PROCEDURES
PCI was performed according to current guidelines. Thrombus 
aspiration, predilation, and post-dilatation were performed 
according to the discretion of the operator. Staged repeat revas-
cularisation procedures with the assigned study stent were sched-
uled within three months of the index procedure. Patients were 
treated with unfractionated heparin with a dose of 5,000 IU or 
70-100 IU/kg body weight during the procedure. The admin-
istration of bivalirudin instead of unfractionated heparin was 
allowed. Administration of glycoprotein IIb/IIIa inhibitors was 
left to the discretion of the operator. Antiplatelet therapy was initi-
ated upstream or at the time of primary PCI. Acetylsalicylic acid 
(≥250 mg) was combined with clopidogrel (loading dose 600 mg, 
maintenance dose 75 mg QD), prasugrel (loading dose 60 mg, 
maintenance dose 10 mg QD), or ticagrelor (loading dose 180 mg, 
maintenance dose 90 mg BID). After a recommended dual anti-
platelet therapy of 12 months duration, monotherapy with acetyl-
salicylic acid was continued indefinitely.
DEFINITIONS AND DATA MANAGEMENT
Definitions of primary and secondary endpoints have been out-
lined previously11. Target lesion failure was the pre-specified pri-
mary endpoint and was a composite of cardiac death, target vessel 
myocardial infarction, and clinically indicated target lesion revas-
cularisation (TLR) within 12 months. Cardiac death was defined 
as any death due to an immediate cardiac cause, death related to 
the procedure, unwitnessed death, and death of unknown cause. 
Spontaneous myocardial infarction was recorded in case of a typi-
cal rise and fall of creatinine kinase MB fraction or troponin in 
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the presence of at least one of the following: ischaemic symp-
toms, new pathologic Q-waves, ischaemic electrocardiographic 
changes or pathological evidence of acute myocardial infarction. 
Periprocedural myocardial reinfarction in the setting of evolving 
myocardial infarction was defined as recurrent chest pain last-
ing >20 minutes (or new ECG changes consistent with myocar-
dial infarction) in combination with a >50% increase of peak CK 
(or CK-MB in the absence of CK) level above the previous level 
measured within 24 hours after the event. In case elevated CK 
(or CK-MB) levels from the index infarction were falling or had 
returned to normal, a reinfarction was diagnosed in case of new 
elevation of CK >2x the upper limit of normal (ULN) if the CK 
level had returned to <ULN, or a rise by >50% above the previ-
ous nadir level if the CK level had not returned to <ULN. A myo-
cardial infarction was related to the target vessel if it could not 
be clearly related to another vessel. TLR was documented in case 
of any repeat percutaneous or surgical intervention secondary to 
a stenosis within the stent or within the 5 mm borders proximal or 
distal to the stent. TLR was regarded as clinically indicated if the 
stenosis of the treated lesion was ≥50% of the lumen diameter in 
the presence of signs or symptoms of ischaemia, or if the diam-
eter stenosis was ≥70% irrespective of the presence or absence of 
ischaemic signs and symptoms.
All data were entered into a web database held at the 
Clinical Trials Unit and the Department of Cardiology in Bern, 
Switzerland. Regular follow-up was performed at 30 days and one 
year. Electrocardiograms were systematically recorded at baseline, 
after the procedure, at 12-month follow-up and in case of recur-
rent signs or symptoms of ischaemia. Data monitoring and event 
adjudication have been described previously.
STATISTICAL ANALYSIS
The BIOSCIENCE trial was powered for non-inferiority on the 
primary clinical endpoint, target lesion failure at 12 months, in 
the overall population but not in the pre-specified subgroup of 
STEMI patients. Based on event rates reported from COMPARE12, 
RESOLUTE All-Comers9, and the LESSON registry13, a TLF rate 
of 8% at 12 months was assumed in both treatment arms. Using 
a margin of 3.5% for non-inferiority of BP-SES vis-à-vis DP-EES, 
enrolment of 2,060 patients was calculated to provide at least 80% 
power to detect non-inferiority at a one-sided type I error of 0.05.
The STEMI population was a pre-specified subgroup with a sig-
nificant interaction effect (STEMI yes or no vs. randomised stent) 
reported for the primary outcome10, which warranted a more in-
depth assessment of clinical outcomes reported here. Clinical 
endpoints were analysed according to the intention-to-treat prin-
ciple. We used the Mantel-Cox method to calculate rate ratios 
(RR), two-sided 95% confidence intervals (CI) and correspond-
ing two-sided p-values for superiority from the log-rank test. We 
used time to first event for each type of outcome throughout, and 
report Kaplan-Meier estimates of event rates. All analyses of end-
points were performed according to the intention-to-treat prin-
ciple. Analyses were undertaken by a statistician of the Clinical 
Trials Unit Bern in Stata version 13 (StataCorp LP, College 
Station, TX, USA). All p-values and CIs are reported two-sided. 
P-values for characteristics recorded at the patient level are from 
unpaired t-tests, chi-square tests, or Fisher’s exact tests, except 
when specified. P-values for characteristics that were recorded at 
the lesion level are from general or generalised linear mixed mod-
els to account for the non-independence of lesions within the same 
patient.
Results
Among 2,119 patients randomly assigned to treatment with 
BP-SES or DP-EES between February 2012 and May 2013, 
407 patients (19%) presented with STEMI. Two hundred and 
eleven STEMI patients with 289 lesions were allocated to treat-
ment with BP-SES, and 196 STEMI patients with 267 lesions 
were allocated to treatment with DP-EES (Figure 1).
Baseline clinical characteristics were comparable between the 
two treatment arms (Table 1). The time interval from pain onset to 
presentation was ≤6 hours in 111 (70%) patients with BP-SES and 
89 (61%) patients with DP-EES. The median door-to-balloon time 
amounted to 53 (interquartile range [IQR] 32-93) minutes in the 
BP-SES group and 51 (IQR 33-95) minutes in the DP-EES group, 
respectively. More than 98% of patients were in Killip class I or II 
in both treatment groups at the time of primary PCI. Angiographic 
and procedural features were similar between the two treatment 
arms with the exception of a higher number of small vessels per 
lesion among patients treated with DP-EES as compared with 
BP-SES (84 [32%] versus 57 [21%], p=0.01) and a smaller max-
imal stent diameter (3.1±0.5 mm versus 3.2±0.5 mm, p=0.01), 
respectively (Table 2). Medical treatment during the procedure and 
throughout follow-up is summarised in Table 3 without significant 
differences. There were no differences in periprocedural antiplate-
let and antithrombotic therapy between groups. The majority of 
patients were loaded with a novel P2Y12 inhibitor primarily, or in 
addition to clopidogrel. Glycoprotein IIb/IIIa inhibitors were used 
in 24.2% of patients treated with BP-SES and 16.3% of patients 
treated with DP-EES (p=0.06). Periprocedural antithrombotic 
treatment consisted of unfractionated heparin in the overwhelming 
majority of patients.
Clinical outcome is summarised in Table 4 and illustrated in 
Figure 2. Among STEMI patients, the primary endpoint TLF 
occurred in seven (3.4%) patients treated with BP-SES and 17 
(8.8%) patients treated with DP-EES at one year (RR 0.38, 95% 
CI: 0.16-0.91, p=0.024). The rates of the individual components 
of the composite endpoint TLF are summarised in Figure 2. There 
was a non-significant trend towards lower rates of cardiac death 
(BP-SES three [1.5%] versus DP-EES nine [4.7%], RR 0.31, 95% 
CI: 0.08-1.14, p=0.062) and target vessel myocardial infarction 
(BP-SES one [0.5%] versus DP-EES five [2.6%], RR 0.18, 95% 
CI: 0.02-1.57, p=0.082) in patients treated with BP-SES. Rates of 
clinically indicated TLR were 1.5% in the BP-SES group versus 
2.1% in the DP-EES group (RR 0.69, 95% CI: 0.16-3.10, p=0.631). 
Rates of definite, probable, and possible stent thrombosis (ST) at 
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     Number at risk
     DP-EES 196 189 185 184 183 183 183 182 181 177 177 175 172
     BP-SES 211 207 201 199 198 198 198 198 197 196 194 194 194
     Number at risk
     DP-EES 196 191 189 188 187 187 187 187 187 184 184 183 180
     BP-SES 211 207 203 202 201 201 201 201 201 200 198 198 197
     Number at risk
     DP-EES 196 189 187 186 185 185 185 184 183 180 180 178 175
     BP-SES 211 207 202 201 200 200 200 200 200 199 197 197 196
     Number at risk
     DP-EES 196 190 186 185 184 184 184 184 184 180 180 178 175
     BP-SES 211 207 202 200 199 199 199 199 198 197 195 195 195
Figure 2. Time-to-event curves for the composite endpoint target lesion failure and individual components of the primary endpoint up to 
12 months of follow-up. A) Target lesion failure. B) Cardiac death. C) Target vessel (TV) myocardial infarction. D) Clinically indicated target 
lesion revascularisation (TLR) or emergent coronary artery bypass surgery (CABG). Blue lines indicate BP-SES, red lines indicate DP-EES.
2,129 patients were randomised
2,119 patients, including 407 STEMI patients
211 were allocated to BP-SES (289 lesions)
210 received at least one BP-SES stent (288 lesions)
210 received only BP-SES stent (288 lesions)
    1 had PCI, but received no stent (1 lesion)
6 lost to follow-up before 1 year
1 refused follow-up
204 follow-up information for clinical primary endpoint 
       available up to 1 year
198 followed up and alive
    6 followed up and died
211 analysed for primary clinical endpoint
    7 censored at time point of refusal or loss to follow-up
10 provided preliminary consent, but
     refused definite consent
  3 randomly allocated to BP-SES
  7 randomly allocated to DP-EES
196 were allocated to DP-EES (267 lesions)
193 received at least one DP-EES stent (262 lesions)
192 received only DP-EES stent (261 lesions)
    1 received DP-EES stent with BMS (1 lesion)
    3 received BP-SES stent (5 lesions)
5 lost to follow-up at 1 year
O refused follow-up
191 follow-up information for clinical primary endpoint 
        available up to 1 year
182 followed up and alive
    9 followed up and died
196 analysed for primary clinical endpoint
    5 censored at time point of refusal or loss to follow-up
Figure 1. Patient flow according to the CONSORT statement. BP-SES: biodegradable polymer sirolimus-eluting stent; DP-EES: durable 
polymer everolimus-eluting stent
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different time points are summarised in Table 5. Whereas there 
were no differences in rates of definite ST, rates of definite or 
probable ST were numerically more frequent in the DP-EES treat-
ment arm at one year.
Discussion
In the pre-specified subgroup analysis of the randomised 
BIOSCIENCE trial, BP-SES was associated with a lower rate of the 
primary endpoint TLF at one year compared to DP-EES. Differences 
Table 1. Baseline clinical characteristics.
Biodegradable polymer 
sirolimus-eluting stent
n=211
Durable polymer everolimus-
eluting stent
n=196
p-value
Age, years (SD) 61.3±12.4 61.7±12.7 0.75
Male gender, n (%) 170 (80.6%) 151 (77.0%) 0.40
Body mass index, kg/m2 27.0±4.3* 27.0±4.3** 0.94
Diabetes mellitus, n (%) 30 (14.2%) 27 (13.8%) 1.00
Hypertension, n (%) 102 (48.6%)∆ 98 (50.3%)∆∆ 0.77
Hypercholesterolaemia, n (%) 110 (52.1%) 101 (51.5%) 0.92
Current smoker, n (%) 93 (44.1%) 77 (39.5%)∆∆ 0.37
Family history of CAD, n (%) 42 (20.1%)* 45 (23.0%) 0.55
Previous MI, n (%) 10 (4.7%) 9 (4.6%) 1.00
Previous PCI, n (%) 12 (5.7%) 8 (4.1%) 0.50
Previous CABG, n (%) 5 (2.4%) 1 (0.5%) 0.22
Previous stroke or TIA, n (%) 2 (0.9%) 3 (1.5%) 0.68
Peripheral vascular disease, n (%) 3 (1.4%) 2 (1.0%) 1.00
Renal failure (GFR <60 ml/min), n (%) 15 (7.7%)‡ 17 (9.6%)‡‡ 0.58
Left ventricular ejection fraction,% 49.5±10.9¶ 48.3±11.1¶¶ 0.32
Clinical presentation
Time to balloon inflation (from symptom onset), min 248 (165-470)# 284 (162-534)## 0.48
Pain onset to balloon 0.12
0-6 hrs 111 (70.3%)# 89 (61.4%)##
>6-12 hrs 24 (15.2%) 38 (26.2%)
>12-24 hrs 21 (13.3%) 17 (11.7%)
>24 hrs 2 (1.3%) 1 (0.7%)
Time from arrival at hospital to balloon inflation, min 53 (32-94) 51 (33-95) 0.87
Killip class 0.77
Killip class I 181 (85.8%) 168 (87.5%)
Killip class II 26 (12.3%) 21 (10.9%)
Killip class III 3 (1.4%) 3 (1.6%)
Killip class IV 1 (0.5%) 0 (0.0%)
Baseline medications, n (%)
Aspirin 41 (19.8%)§ 31 (16.3%)§§ 0.43
Clopidogrel 2 (1.0%)§ 4 (2.1%)§§ 0.43
Prasugrel 1 (0.5%)§ 4 (2.1%)§§ 0.20
Ticagrelor 4 (1.9%)§ 2 (1.1%)§§ 0.69
Any dual antiplatelet treatment 6 (2.9%)§ 8 (4.2%)§§ 0.58
Oral anticoagulants - vitamin K antagonists 1 (0.5%)§ 2 (1.1%)§§ 0.61
Novel oral anticoagulants 0 (0.0%)◊ 0 (0.0%)§§
Any antithrombotic treatment 1 (0.5%)§ 2 (1.1%)§§ 0.61
Statins 34 (16.5%)◊ 35 (18.4%)§§ 0.69
ACE inhibitors or receptor blockers 27 (13.1%)◊ 23 (12.1%)§§ 0.88
Beta-blockers 28 (13.6%)◊ 34 (17.9%)§§ 0.27
Data expressed as n (%), means±standard deviation or medians (25%-75% interquartile range). p-values from Fisher’s tests, unpaired t-tests and Mann-
Whitney U tests, respectively. *n: 209; ∆n: 210; ‡n: 196; ¶n: 167; #n: 158; §n: 207; ◊n: 206; **n: 193; ∆∆n: 195; ‡‡n: 177; ¶¶n: 157; ##n: 145; §§n: 190.
EuroIntervention 2
0
16
;1
2
:e
13
4
3
-e
13
5
4
e1348
Table 2. Angiographic and procedural characteristics.
No. of patients
Biodegradable polymer 
sirolimus-eluting stent
n=211
Durable polymer 
everolimus-eluting stent
n=196
p-value
Lesions, n n=289 n=267
Target vessel location per lesion∆, n (%) n=289 n=267 0.10
Left main artery 6 (2.1%) 4 (1.5%)
Left anterior descending artery 109 (37.7%) 115 (43.1%)
Left circumflex artery 47 (16.3%) 55 (20.6%)
Right coronary artery 124 (42.9%) 93 (34.8%)
Saphenous vein graft 3 (1.0%) 0 (0.0%) 0.25
No. of treated lesions per patient¶ 1.37±0.73 1.36±0.62 0.95
Number of treated lesions per patient∆, n (%) n=211 n=196 0.95
One 155 (73.5%) 140 (71.4%)
Two 41 (19.4%) 41 (20.9%)
Three 10 (4.7%) 15 (7.7%)
≥Four 5 (2.4%) 0 (0.0%)
Type of intervention per lesion, n (%)** n=289 n=267 0.36
Stent implantation 276 (95.5%) 259 (97.0%)
PTCA 12 (4.2%) 8 (3.0%)
Failed PCI 1 (0.3%) 0 (0.0%)
Baseline TIMI flow per lesion, n (%) n=282 n=263 0.23
0 or 1 163 (57.8%) 136 (51.7%)
2 37 (13.1%) 47 (17.9%)
3 82 (29.1%) 80 (30.4%)
TIMI flow post intervention per lesion, n (%) n=287 n=267 0.79
0 or 1 2 (0.7%) 3 (1.1%)
2 7 (2.4%) 5 (1.9%)
3 278 (96.9%) 259 (97.0%)
Thrombus aspiration per lesion, n (%) 115 (39.8%) 92 (34.7%)# 0.22
Number of stents per lesion, mean (SD) 1.42±0.71◊ 1.39±0.71◊◊ 0.71
Total stent length per lesion, mm 29.49±17.83◊ 30.52±18.99◊◊ 0.51
Maximum stent diameter per lesion, mm 3.18±0.48◊ 3.06±0.52◊◊ 0.01
Maximum pressure per lesion, atm 13.86±3.36◊ 13.39±3.20◊◊ 0.11
Overlapping stents per lesion, n (%) 83 (30.1%)◊ 62 (23.9%)◊◊ 0.14
Direct stenting per lesion, n (%) 78 (28.3%)◊ 68 (26.3%)◊◊ 0.62
Long lesion per lesion (>20 mm), n (%) 171 (62.0%)◊ 170 (65.6%)◊◊ 0.38
Small vessel per lesion (<2.75 mm), n (%) 57 (20.7%)◊ 84 (32.4%)◊◊ 0.01
Type of stent per lesion∆, (%) 0.053∆∆
Study stent BP-SES 276 (100.0%) 5 (1.9%)
Study stent DP-EES 0 (0.0%) 254 (98.1%)
Other drug-eluting stent 0 (0.0%) 0 (0.0%)
Bare metal stent 0 (0.0%) 1 (0.4%)
 IABP per patient, n (%) 1 (0.5%) 0 (0.0%) 1.00∆
 Vasopressors per patient, n (%) 4 (1.9%) 1 (0.5%) 0.24
Data expressed as n (%) or means±standard deviation. p-values from ¶Poisson regression and ∆chi-square tests or Fisher's test; otherwise, p-values from 
mixed models for the per-lesion analyses, accounting for lesions nested within patients: general linear mixed models for continuous variables, 
generalised linear mixed models for counts no. Long lesion: total stent length >20 mm. Small vessel: minimum stent diameter <2.75 mm. ** In one 
patient randomised to stent DP-EES one lesion, the intervention was aborted. ∆∆ One patient randomised to stent DP-EES contained stent DP-EES and 
BMS within same lesion. p-value for any non-randomised stent implanted per patient. ◊n: 276; #n: 265; ◊◊n: 259.
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in the primary endpoint were driven by non-significant, numerical 
differences in cardiac death and target vessel myocardial infarction, 
whereas there was no difference in repeat revascularisation.
The antirestenotic efficacy of early-generation durable poly-
mer sirolimus-eluting stents (DP-SES) in the setting of STEMI 
came at the expense of an excess in late thrombotic events14. In 
the LEADERS (Limus Eluted from A Durable versus ERodable 
Stent coating) trial15, which compared biodegradable poly-
mer biolimus-eluting stents (BP-BES) with early-generation 
DP-SES, a lower rate of the primary endpoint MACE among 
BP-BES treated patients was documented in the subgroup of 
STEMI at nine months, a finding which was maintained during 
Table 3. Medical treatment.
No. of patients
Biodegradable polymer 
sirolimus-eluting stent
n=211
Durable polymer 
everolimus-eluting stent
n=196
p-value
During primary 
PCI, n (%)
Aspirin 209 (99.1%) 194 (99.0%) 1.00
Clopidogrel 69 (32.7%) 64 (32.7%) 1.00
Prasugrel 141 (66.8%) 141 (71.9%) 0.28
Ticagrelor 46 (21.8%) 35 (17.9%) 0.39
Unfractionated heparin 206 (97.6%) 193 (98.5%) 0.73
Low-molecular-weight heparin (LMWH) 8 (3.8%) 10 (5.1%) 0.63
Bivalirudin 3 (1.4%) 3 (1.5%) 1.00
Glycoprotein IIb/IIIa inhibitors 51 (24.2%) 32 (16.3%) 0.06
At discharge, 
n (%)
Aspirin 209 (99.1%)* 195 (100.0%)¶ 0.50
Clopidogrel 17 (8.1%)* 15 (7.7%)¶ 1.00
Prasugrel 145 (68.7%)* 145 (74.4%)¶ 0.23
Ticagrelor 48 (22.7%)* 36 (18.5%)¶ 0.33
Any dual antiplatelet treatment 207 (98.1%)* 195 (100.0%)¶ 0.12
Vitamin K oral anticoagulants 9 (4.3%)* 7 (3.6%)¶ 0.80
Non-vitamin K oral anticoagulants (NOAC) 1 (0.5%)* 1 (0.5%)¶ 1.00
Any antithrombotic treatment 10 (4.7%)* 8 (4.1%)¶ 0.81
Statin 207 (98.1%)* 190 (97.4%)¶ 0.74
ACE inhibitor 181 (85.8%)* 162 (83.1%)¶ 0.49
Beta-blocker 187 (88.6%)* 178 (91.3%)¶ 0.41
At 30-day 
follow-up, n (%)
Aspirin 204 (99.0%)‡ 191 (99.5%)‡‡ 1.00
Clopidogrel 23 (11.2%)‡ 19 (9.9%)‡‡ 0.75
Prasugrel 140 (68.0%)‡ 141 (73.4%)‡‡ 0.27
Ticagrelor 43 (20.9%)‡ 32 (16.7%)‡‡ 0.31
Any dual antiplatelet treatment 203 (98.5%)‡ 190 (99.0%)‡‡ 1.00
Oral anticoagulants 11 (5.3%)‡ 7 (3.6%)‡‡ 0.48
Novel oral anticoagulants 0 (0.0%)‡ 1 (0.5%)‡‡ 0.48
Any antithrombotic treatment 11 (5.3%)‡ 8 (4.2%)‡‡ 0.64
Statin 200 (97.1%)‡ 183 (95.3%)‡‡ 0.43
ACE inhibitor 165 (80.1%)‡ 143 (74.5%)‡‡ 0.19
Beta-blocker 179 (86.9%)‡ 173 (90.1%)‡‡ 0.35
At 1-year 
follow-up, n (%)
Aspirin 192 (97.0%)# 177 (97.3%)## 1.00
Clopidogrel 30 (15.2%)# 23 (12.6%)## 0.55
Prasugrel 122 (61.6%)# 112 (61.5%)## 1.00
Ticagrelor 31 (15.7%)# 29 (15.9%)## 1.00
Any dual antiplatelet treatment 178 (89.9%)# 158 (86.8%)## 0.42
Oral anticoagulants 8 (4.0%)# 7 (3.8%)## 1.00
Novel oral anticoagulants 1 (0.5%)# 2 (1.1%)## 0.61
Any antithrombotic treatment 9 (4.5%)# 9 (4.9%)## 1.00
Statin 183 (92.9%)# 174 (95.6%)## 0.28
ACE inhibitor 140 (70.7%)# 112 (61.9%)## 0.08
Beta-blocker 156 (78.8%)# 158 (86.8%)## 0.04
*n: 194; ¶n: 195; ‡n: 206; #n: 198; ‡‡n: 192; ##n: 182.
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long-term follow-up throughout five years16. The present study 
may extend the potential benefit of biodegradable polymer-
based DES among STEMI patients observed with early-genera-
tion thick-strut stainless steel DES to newer-generation thin-strut 
cobalt-chromium DES. Noteworthy, cobalt-chromium DP-EES 
currently represent the benchmark for safety and efficacy in 
STEMI patients undergoing primary PCI, as suggested by recent 
network meta-analyses17,18.
An individual patient-data, pooled analysis of 497 patients 
with STEMI from three trials randomly comparing thick-strut 
stainless steel BP-DES with early-generation, thick-strut DP-SES 
observed a benefit of BP-DES with a difference emerging within 
one year after primary PCI (BP-DES 27 [9.4%] versus early-
generation DP-SES 32 [15.8%], HR 0.58, 95% CI: 0.35-0.93, 
p=0.03), whereas there was no difference in the period between 
one and four years (BP-DES 13 [5.2%] versus early-generation 
DP-SES 14 [8.6%], HR 0.62, 95% CI: 0.29-1.31, p=0.21). In 
contrast to the present analysis, the effect within the first year 
was driven by a lower rate of repeat revascularisation (TLR: 
BP-DES 12 [4.4%] versus early-generation DP-SES 19 [9.7%], 
HR 0.43, 95% CI: 0.21-0.89, p=0.02), while no difference 
was observed in rates of cardiac death or myocardial infarc-
tion6. A trend towards a lower rate of definite stent thrombo-
sis in the first year after stent implantation documented in the 
pooled analysis (BP-DES eight [2.9%] versus early-generation 
DP-SES 13 [6.5%], HR 0.43, 95% CI: 0.18-1.03, p=0.06) was 
also seen in the present subgroup analysis6. Five-year outcomes 
of the LEADERS trial showed significantly improved safety and 
Table 4. Clinical outcomes at 12 months after stent implantation.
Biodegradable polymer 
sirolimus-eluting stent
n=211
Durable polymer 
everolimus-eluting stent
n=196
Rate ratio  
[SES/EES]
(95% CI)
p-value
All-cause death 6 (2.9) 9 (4.7) 0.62 (0.22-1.74) 0.357
Cardiac death 3 (1.5) 9 (4.7) 0.31 (0.08-1.14) 0.062
Reinfarction (any) 3 (1.5) 5 (2.6) 0.55 (0.13-2.32) 0.412
Q-wave 0 (0.0) 3 (1.6) 0.13 (0.01-2.50) 0.111
Non-Q-wave 3 (1.5) 2 (1.1) 1.40 (0.23-8.42) 0.710
Target vessel reinfarction 1 (0.5) 5 (2.6) 0.18 (0.02-1.57) 0.082
Q-wave 0 (0.0) 3 (1.6) 0.13 (0.01-2.50) 0.111
Non-Q-wave 1 (0.5) 2 (1.1) 0.47 (0.04-5.12) 0.522
Cardiac death or MI 6 (2.9) 14 (7.3) 0.39 (0.15-1.03) 0.048
Any repeat revascularisation 10 (4.9) 9 (4.7) 1.02 (0.41-2.51) 0.964
Any target lesion revascularisation 3 (1.5) 5 (2.7) 0.55 (0.13-2.31) 0.410
Clinically indicated TLR 3 (1.5) 4 (2.1) 0.69 (0.16-3.10) 0.631
Clinically indicated TVR 6 (3.0) 5 (2.7) 1.12 (0.34-3.66) 0.857
Any target vessel revascularisation 6 (3.0) 6 (3.2) 0.92 (0.30-2.87) 0.891
Clinically indicated TLR or clinically indicated 
surgical TVR 3 (1.5) 5 (2.7) 0.55 (0.13-2.32) 0.412
Cerebrovascular event* 4 (2.0) 4 (2.1) 0.93 (0.23-3.71) 0.913
Target lesion failure** 7 (3.4) 17 (8.8) 0.38 (0.16-0.91) 0.024
Target vessel failure*** 10 (4.9) 18 (9.3) 0.51 (0.24-1.11) 0.082
Death, MI, or any repeat revascularisation**** 17 (8.3) 19 (9.8) 0.82 (0.43-1.59) 0.563
BARC bleeding events type 3-5 9 (4.4) 10 (5.2) 0.83 (0.34-2.06) 0.694
BARC bleeding type 3a 4 (1.9) 3 (1.6) 1.24 (0.28-5.56) 0.777
BARC bleeding type 3b 4 (2.0) 7 (3.7) 0.53 (0.15-1.80) 0.299
BARC bleeding type 3c 0 (0.0) 0 (0.0)
BARC bleeding type 4 1 (0.5) 0 (0.0) 2.79 (0.11-68.08) 1.000
BARC bleeding type 5a 0 (0.0) 0 (0.0)
BARC bleeding type 5b 0 (0.0) 0 (0.0)
Number of first events and percentages are reported. Rate ratios (RR; 95% CI) are estimated using the Mantel-Cox method with two-sided p-values from 
log-rank test. All events were censored beyond 365 days. Continuity corrected RR with Fisher’s exact test for zero outcomes. MI: myocardial infarction; 
TLR: target lesion revascularisation; TVR: target vessel revascularisation. *Includes ischaemic stroke, intracerebral haemorrhage and unclear aetiology 
CVE. **Primary endpoint, defined as the composite of cardiac death, target vessel Q-wave or non-Q-wave MI, clinically indicated TLR and clinically 
indicated surgical TVR. ***Defined as the composite of cardiac death, any Q-wave or non-Q-wave MI, and any TVR. ****Patient-oriented composite 
endpoint.
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efficacy outcomes in patients with STEMI treated with BP-BES 
as compared to early-generation DP-SES, driven by a lower rate 
of cardiac death (BP-BES four [3%] versus DP-SES 16 [11.4%], 
p=0.007) and revascularisation (BP-BES 14 [17.8%] versus 37 
[26.4%], p=0.049)7. It remains to be determined whether these 
findings are a class effect of biodegradable polymer DES in gen-
eral, or whether the properties are inherent to individual stents 
specifically.
Biodegradable polymers may have favourable results on arterial 
healing after DES implantation. In the optical coherence tomog-
raphy substudy of the LEADERS trial5, a favourable healing 
response was observed with BP-BES compared with early-gen-
eration DP-SES at nine months. The effect of an enhanced heal-
ing response may be augmented in the inflammatory milieu of 
STEMI. Evidence of adverse arterial remodelling among patients 
with STEMI has been shown by a greater degree of incomplete 
DES apposition and delayed tissue coverage compared to patients 
with stable or unstable angina in optical coherence tomography 
studies1,19. However, while sirolimus is released over a period of 
12 to 14 weeks, the PLLA polymer matrix degrades over a period 
of 12 to 24 months, and may not fully account for the observed 
difference. In addition to the biodegradable polymer, the reduced 
strut thickness of the novel stent platform as well as the pas-
sive stent coating may play a role when implanted into lesions 
of patients with STEMI, by reducing acute arterial injury and the 
risk for peripheral embolisation as well as affording a more rapid 
re-endothelialisation. A reduction of strut thickness in the case of 
BMS has been associated with a lower risk of restenosis20 and 
attenuated thrombogenicity21.
Limitations
The present analysis has several limitations. First, the 
BIOSCIENCE trial was not powered to assess differences in clin-
ical outcome among patients with STEMI and therefore findings 
may be due to chance alone. However, randomisation was pre-
specified for the presence or absence of STEMI and there were 
no differences in evidence-based medical therapy. Furthermore, 
event rates were consistent with event rates of recent STEMI 
trials (Table 6). Second, patients in the DP-EES treatment arm 
had a higher proportion of small vessel disease and a smaller 
Table 5. Stent thrombosis.
Biodegradable polymer 
sirolimus-eluting stent
n=211
Durable polymer 
everolimus-eluting stent
n=196
Rate ratio [SES/EES]
(95% CI)
p-value
Definite stent 
thrombosis¶
0 to 30 days 0 (0.0) 1 (0.5) 0.31 (0.01-7.56) 0.482
>30 days to 12 months 0 (0.0) 1 (0.5) 0.31 (0.01-7.56) 0.480
0 days to 12 months 0 (0.0) 2 (1.0) 0.19 (0.01-3.93) 0.231
Probable stent 
thrombosis
0 to 30 days 2 (1.0) 4 (2.0) 0.46 (0.08-2.51) 0.358
>30 days to 12 months 1 (0.5) 3 (1.6) 0.31 (0.03-2.96) 0.280
0 days to 12 months 3 (1.4) 7 (3.6) 0.39 (0.10-1.53) 0.163
Possible stent 
thrombosis
0 to 30 days 0 (0.0) 0 (0.0)
>30 days to 12 months 1 (0.5) 5 (2.6) 0.19 (0.02-1.59) 0.085
0 days to 12 months 1 (0.5) 5 (2.6) 0.19 (0.02-1.59) 0.085
Definite or probable 
stent thrombosis
0 to 30 days 2 (1.0) 5 (2.6) 0.37 (0.07-1.89) 0.212
>30 days to 12 months 1 (0.5) 4 (2.2) 0.23 (0.03-2.05) 0.150
0 days to 12 months 3 (1.4) 9 (4.7) 0.31 (0.08-1.13) 0.060
Number of first events and percentages are reported. Rate ratios (RR) are estimated using the Mantel-Cox method with two-sided p-values from log-rank 
test, except ¶ continuity corrected RR with p-values from Fisher’s test. Possible stent thrombosis cannot occur by definition within 30 days. Landmark 
used at 30 days for >30 days to 12 months analyses, and note that the risk set for each risk difference calculation changes accordingly.
Table 6. Event rates in recent STEMI trials (%).
MULTISTRATEGY22** 
(BMS/SES)
DEDICATION23**  
(DES/BMS)
HORIZONS24*  
(PES/BMS)
EXAMINATION8*  
(EES/BMS)
COMFORTABLE4* 
(BES/BMS)
BIOSCIENCE*  
 (SES/EES)
Death 2.2/1.3 5.2/2.6 3.5/3.5 3.5/3.5 3.2/4.1 2.9/4.7
Cardiac death – 4.2/1.6 2.4/2.7 3.2/2.8 2.9/3.5 1.5/4.7
Reinfarction 2.7/1.3 1.0/1.9 3.7/4.5 1.3/2.0 2.0/3.7 1.5/2.6
TV reinfarction – – – 1.1/2.0 0.5/2.7 0.5/2.6
* follow-up to 12 months; ** follow-up to 8 months; TV: target vessel
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maximum stent diameter that may have affected clinical outcome. 
Moreover, there was a trend towards a more frequent administra-
tion of glycoprotein IIb/IIIa inhibitors in the group of patients 
treated with BP-SES. Third, the STEMI patients included in the 
BIOSCIENCE trial were rather low risk based on Killip class; 
generalisability to a higher-risk population therefore requires 
confirmation in registries including higher-risk patients. Finally, 
the duration of follow-up was limited to 12 months, which may 
not suffice to assess the efficacy of BP-SES beyond complete 
degradation of the biodegradable polymer.
Conclusion
In conclusion, BP-SES may be associated with improved clinical 
outcomes compared with DP-EES among STEMI patients undergo-
ing primary PCI. The findings are hypothesis-generating and have 
to be reproduced in a dedicated, randomised trial in order to sub-
stantiate the potential benefit of BP-SES in patients with STEMI.
Impact on daily practice
The use of a thin-strut biodegradable polymer sirolimus-eluting 
stent (Orsiro BP-SES) in patients with acute ST-segment eleva-
tion myocardial infarction (STEMI) is safe and effective. In this 
pre-specified analysis of the BIOSCIENCE trial, the BP-SES 
had a similar performance compared with the durable polymer 
everolimus-eluting stents, with a significant reduction in the risk 
of target lesion failure. This finding needs confirmation at long-
term follow-up and warrants further clinical evaluation in an 
appropriate randomised trial. However, the Orsiro BP-SES is 
currently a reasonable alternative when implanted in the STEMI 
setting.
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